DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the European Academy of Allergy and Clinical Immunology (EAACI) congress
BAGNEUX, France, June 18, 2012 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the presentation for the first time of the detailed results of its phase Ib clinical study completed earlier this year, representing the first clinical study showing the safety and well-tolerability of Viaskin® in peanut-allergic patients. DBV Technologies also continued to showcase its knowledge in the cellular mechanism implicated during the specific EPIT process and in the Viaskin® Technology with four additional communications presented during the congress.
